1. Executive Session 6:00 - 6:30

2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:35 - 6:40
   - Updates

4. Medical Director Update 6:40 – 6:45
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings 6:45 – 7:00
   - VDH Asthma Program- Rhonda Williams

6. RetroDUR/DUR 7:00 – 7:20
   - Appropriate use of Asthma controller medication
   - Use of Valproic Acid in Women of Child-bearing Age
   - Use of Butalbital-containing medications

7. Clinical Update: Drug Reviews 7:20 – 7:45
   (Public comment prior to Board action)

   Abbreviated New Drug Reviews
   - None

   Full New Drug Reviews
   - Aristada® Inj (aripiprazole lauroxill)
   - Narcan® NS (naloxone)
   - Synjardy® tabs (empagliflozin/metformin hydrochloride)
   - Zecuity® transdermal (sumatriptan iontophoretic transdermal system)

8. Therapeutic Drug Classes – Periodic Review 7:45 – 8:20
   (Public comment prior to Board action)
   - Androgenic Agents
   - Antibiotics, Topical
- Hemophilia Factors
- Prenatal Vitamins
- Steroids, Topical

9. New Managed Therapeutic Drug Classes 8:20 – 8:20
   (Public comment prior to Board action)

10. Review of Newly-Developed/Revised 8:20-8:20
    Clinical Coverage Criteria and/or Preferred Products
    (Public comment prior to Board action)

11. General Announcements 8:20 – 8:30
    Selected FDA Safety Alerts

    Eye Drops: FDA Statement - Potential Risk of Loose Safety Seals

    Fluconazole Injection, USP, (in 0.9 Percent Sodium Chloride) 200mg per 100ml: Recall - Elevated Impurity

12. Adjourn 8:30